AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25527907 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous-scale tumour size
Number of subjects: 464
Study 25529193 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 831266 (130 mg)
Number of subjects: 25
Study 25529193 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 831266 (various doses 4-130 mg)
Number of subjects: 25
Study 25529193 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 831266 (various doses)
Number of subjects: 25
Study 25529193 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 831266 (32 mg)
Number of subjects: 25
Study 25529339 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose MSCs (1 million cells/kg PBW)
Number of subjects: 9
Study 25529339 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate dose MSCs (5 million cells/kg PBW)
Number of subjects: 9
Study 25529339 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose MSCs (10 million cells/kg PBW)
Number of subjects: 9
Study 25529339 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of MSCs
Number of subjects: 9
Study 25529544 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolically abnormal but normal-weight (MHO)
Number of subjects: 250
Study 25529544 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolically healthy obese (MHO)
Number of subjects: 250
Study 25529544 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolically abnormal obese
Number of subjects: 250
Study 25529544 — intervention group
Group type: COMPARATOR
Intervention: Metabolically healthy normal-weight (MHNW)
Number of subjects: 250
Study 25529885 — intervention group
Group type: EXPERIMENTAL
Intervention: 96-well rapid equilibrium dialysis (RED) method
Number of subjects: 0
Study 25530131 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg once daily
Number of subjects: 52
Study 25531297 — intervention group
Group type: EXPERIMENTAL
Intervention: Cool Challenge (18°C for ≤120 min) in tetraplegics
Number of subjects: 14
Study 25531297 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline (27°C) in tetraplegics
Number of subjects: 14
Study 25531297 — intervention group
Group type: COMPARATOR
Intervention: Cool Challenge (18°C for ≤120 min) in able-bodied controls
Number of subjects: 14
Study 25531297 — intervention group
Group type: COMPARATOR
Intervention: Baseline (27°C) in able-bodied controls
Number of subjects: 14
Study 25531808 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal (ID) injection in forearm and deltoid
Number of subjects: 102
Study 25531808 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (IM) injection in deltoid
Number of subjects: 102
Study 25531808 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal (ID) injection in forearm
Number of subjects: 102
Study 25531894 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabbit antithymocyte globulin (rATG)
Number of subjects: 33
Study 25531960 — intervention group
Group type: EXPERIMENTAL
Intervention: ALO-02 (oxycodone-hydrochloride/naltrexone-hydrochloride)
Number of subjects: 395
Study 25532016 — intervention group
Group type: EXPERIMENTAL
Intervention: Normocaloric Low Cholesterol Diet (NLCD) for 30 days
Number of subjects: 0
Study 25532039 — intervention group
Group type: EXPERIMENTAL
Intervention: Klinefelter syndrome patients
Number of subjects: 132
Study 25532039 — intervention group
Group type: COMPARATOR
Intervention: Male controls
Number of subjects: 132
Study 25532039 — intervention group
Group type: COMPARATOR
Intervention: Female controls
Number of subjects: 132
Study 25532044 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline leptin levels
Number of subjects: 633
Study 25532044 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline IGF-I levels
Number of subjects: 633
Study 25532044 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline iPTH levels
Number of subjects: 633
Study 25532044 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline adiponectin levels
Number of subjects: 633
Study 25532471 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib treatment before surgery
Number of subjects: 72
Study 25533035 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Number of subjects: 102
Study 25533729 — intervention group
Group type: EXPERIMENTAL
Intervention: Twelve-week weight loss intervention, details on dosage and specific methods not provided.
Number of subjects: 0
Study 25533729 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroimaging using Functional Magnetic Resonance Imaging (fMRI) during food and non-food image viewing.
Number of subjects: 0
Study 25533729 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up during a 6-month maintenance period after the weight loss intervention.
Number of subjects: 0
Study 25533886 — intervention group
Group type: EXPERIMENTAL
Intervention: SBT/ABPC 3 g QID intravenously for 3-14 days
Number of subjects: 47
Study 25533902 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii.n.Walk intervention (Nintendo Wii Fit)
Number of subjects: 3
Study 25533902 — intervention group
Group type: COMPARATOR
Intervention: Attention control group (Wii Big Brain cognitive software)
Number of subjects: 3
Study 25534573 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride 2 mg
Number of subjects: 1821
Study 25534573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1821
Study 25535009 — intervention group
Group type: EXPERIMENTAL
Intervention: A homozygotes of rs10779646
Number of subjects: 590
Study 25535009 — intervention group
Group type: EXPERIMENTAL
Intervention: G allele of rs7549184
Number of subjects: 590
Study 25535009 — intervention group
Group type: EXPERIMENTAL
Intervention: STAR*D dataset
Number of subjects: 590
Study 25535041 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV medication adherence intervention program
Number of subjects: 0
Study 25535041 — intervention group
Group type: COMPARATOR
Intervention: Prior published studies
Number of subjects: 0
Study 25535294 — intervention group
Group type: EXPERIMENTAL
Intervention: US smokers; urine NNAL excretion
Number of subjects: 441
Study 25535294 — intervention group
Group type: COMPARATOR
Intervention: Chinese smokers; urine PAH metabolites (fluorene, phenanthrene, pyrene)
Number of subjects: 441
Study 25535398 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT) added to standard therapy
Number of subjects: 0
Study 25535398 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 0
Study 25535398 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT)
Number of subjects: 0
Study 25536209 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) surgery
Number of subjects: 25
Study 25537783 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing quartiles of neighbourhood greenspace
Number of subjects: 10476
Study 25537783 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of neighbourhood greenspace
Number of subjects: 10476
Study 25537783 — intervention group
Group type: COMPARATOR
Intervention: None specified
Number of subjects: 10476
Study 25538134 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-HDI countries
Number of subjects: 9301
Study 25538134 — intervention group
Group type: EXPERIMENTAL
Intervention: High-HDI countries
Number of subjects: 9301
Study 25538134 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-high HDI countries
Number of subjects: 9301
Study 25538134 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-income/middle-income countries
Number of subjects: 9301
Study 25538134 — intervention group
Group type: EXPERIMENTAL
Intervention: High-income countries
Number of subjects: 9301
Study 25538176 — intervention group
Group type: EXPERIMENTAL
Intervention: ipilimumab plus fotemustine
Number of subjects: 86
Study 25538323 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous intravenous administrations of GLP-1
Number of subjects: 0
Study 25538323 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous intravenous administrations of GIP
Number of subjects: 0
Study 25538323 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous intravenous administrations of GLP-1 and GIP
Number of subjects: 0
Study 25538323 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 25538794 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepsis survivors (78 subjects)
Number of subjects: 1152
Study 25538794 — intervention group
Group type: COMPARATOR
Intervention: Sepsis non-survivors (28 subjects)
Number of subjects: 1152
Study 25538794 — intervention group
Group type: EXPERIMENTAL
Intervention: VPS9D1 gene variants in sepsis survivors
Number of subjects: 1152
Study 25538794 — intervention group
Group type: EXPERIMENTAL
Intervention: General gene expression analysis
Number of subjects: 1152
Study 25538794 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional genetic variants
Number of subjects: 1152
Study 25538907 — intervention group
Group type: EXPERIMENTAL
Intervention: Total epithelium off
Number of subjects: 22
Study 25538907 — intervention group
Group type: COMPARATOR
Intervention: Partial epithelial removal
Number of subjects: 22
Study 25539270 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CT angiography (CTA) and perfusion CT
Number of subjects: 381
Study 25539270 — intervention group
Group type: COMPARATOR
Intervention: SPECT
Number of subjects: 381
Study 25539270 — intervention group
Group type: COMPARATOR
Intervention: Diagnostic catheter angiography
Number of subjects: 381
Study 25539270 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CTA and perfusion CT
Number of subjects: 381
Study 25540064 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib 500 mg/day (n = 63)
Number of subjects: 63
Study 25540064 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib 500 mg/day (n = 28, CP 2L)
Number of subjects: 63
Study 25540064 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib 500 mg/day (n = 7, advanced-phase 2L)
Number of subjects: 63
Study 25540064 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib 500 mg/day (n = 11, 3L)
Number of subjects: 63
Study 25540406 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm milk
Number of subjects: 22
Study 25540406 — intervention group
Group type: COMPARATOR
Intervention: Term milk
Number of subjects: 22
Study 25540981 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric diet
Number of subjects: 8
Study 25541100 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenuated MPS II patients
Number of subjects: 20
Study 25541100 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 20
Study 25541444 — intervention group
Group type: EXPERIMENTAL
Intervention: Iliofemoral vein stent placement
Number of subjects: 62
Study 25543678 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 0
Study 25543678 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrates, budesonide, and obeticholic acid
Number of subjects: 0
Study 25544158 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative FA values in PAD patients (mean ± SD 0.370 ± 0.017)
Number of subjects: 24
Study 25544158 — intervention group
Group type: COMPARATOR
Intervention: Healthy age matched participants (15 participants)
Number of subjects: 24
Study 25544296 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic third molars with probing depths <4 mm at enrollment
Number of subjects: 129
Study 25545105 — intervention group
Group type: EXPERIMENTAL
Intervention: FAmily CEntered Advance Care Planning (ACP) for Teens with Cancer (FACE-TC) study
Number of subjects: 17
Study 25545105 — intervention group
Group type: COMPARATOR
Intervention: Post-hoc survey sent to oncology providers
Number of subjects: 17
Study 25545153 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF priming, clofarabine (30 mg m(-2) day(-1) × 5), and cytarabine (2 g m(-2) day(-1) × 5)
Number of subjects: 50
Study 25545153 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF priming, clofarabine, and cytarabine
Number of subjects: 50
Study 25545244 — intervention group
Group type: EXPERIMENTAL
Intervention: peg-proline-IFNα-2b
Number of subjects: 51
Study 25545465 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa intestinal gel (LCIG)
Number of subjects: 354
Study 25546176 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-bolus low-dose contrast injection (1.3 mL and 0.05 mmol/kg of gadobenate dimeglumine)
Number of subjects: 21
Study 25546176 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-bolus acquisition
Number of subjects: 21
Study 25546176 — intervention group
Group type: COMPARATOR
Intervention: Pre-bolus and main bolus acquisitions
Number of subjects: 21
Study 25546395 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DRB1454
Number of subjects: 0
Study 25547133 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC)
Number of subjects: 81
Study 25547338 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS) and room service system care
Number of subjects: 70
Study 25547338 — intervention group
Group type: COMPARATOR
Intervention: Preoperative nutrition risk
Number of subjects: 70
Study 25547501 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem-cell transplantation (SCT) with a sibling donor
Number of subjects: 304
Study 25547501 — intervention group
Group type: COMPARATOR
Intervention: No donor, received consolidation or autologous SCT
Number of subjects: 304
Study 25547501 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic SCT with a sibling donor in patients with normal karyotype and no FLT3 internal tandem duplication
Number of subjects: 304
Study 25547501 — intervention group
Group type: COMPARATOR
Intervention: No donor in patients with normal karyotype and no FLT3 internal tandem duplication
Number of subjects: 304
Study 25547501 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic SCT with a sibling donor
Number of subjects: 304
Study 25547501 — intervention group
Group type: COMPARATOR
Intervention: No donor
Number of subjects: 304
Study 25548919 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional near-infrared spectroscopy (fNIRS) combined with muscle and kinematic monitoring during motor tasks.
Number of subjects: 0
Study 25548978 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum total testosterone (TT) and free testosterone (FT) levels
Number of subjects: 788
Study 25549051 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparous mothers
Number of subjects: 1099
Study 25549051 — intervention group
Group type: EXPERIMENTAL
Intervention: Primiparous mothers
Number of subjects: 1099
Study 25549988 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy AMA women (age > 35 yr)
Number of subjects: 0
Study 25549988 — intervention group
Group type: COMPARATOR
Intervention: Healthy non-AMA women (age ≤ 35 yr)
Number of subjects: 0
Study 25550361 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutations in SRSF2, SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR, or STAG2 in s-AML patients
Number of subjects: 299
Study 25550361 — intervention group
Group type: EXPERIMENTAL
Intervention: s-AML genetic subtype
Number of subjects: 299
Study 25552401 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg/day gefitinib and 400 mg/day vorinostat
Number of subjects: 52
Study 25552401 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg/day gefitinib and 400 mg/day vorinostat in EGFR-mutant NSCLC
Number of subjects: 52
Study 25552483 — intervention group
Group type: EXPERIMENTAL
Intervention: L19-IL2 combined with radiotherapy
Number of subjects: 0
Study 25552564 — intervention group
Group type: EXPERIMENTAL
Intervention: High-BMI group
Number of subjects: 780
Study 25552564 — intervention group
Group type: COMPARATOR
Intervention: Low-BMI group
Number of subjects: 780
Study 25553059 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard diet (33% fat, 52% carbohydrate, 15% protein) for 7 days followed by a test meal (40% fat, 40% carbohydrate, 20% protein) on Day 8.
Number of subjects: 32
Study 25553059 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin sensitivity index (SI) calculated from the minimal model.
Number of subjects: 32
Study 25553059 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral adipose tissue (VAT) measurement.
Number of subjects: 32
Study 25553245 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepsis patients
Number of subjects: 65
Study 25553245 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe sepsis and septic shock patients
Number of subjects: 65
Study 25553245 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepsis patients 48 hours before death
Number of subjects: 65
Study 25553245 — intervention group
Group type: COMPARATOR
Intervention: Metabolic profiling
Number of subjects: 65
Study 25554012 — intervention group
Group type: EXPERIMENTAL
Intervention: PARP inhibition
Number of subjects: 0
Study 25554484 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based interventions (not specified in detail)
Number of subjects: 1118
Study 25555214 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate weight gain (~6%) in MNO subjects
Number of subjects: 20
Study 25555214 — intervention group
Group type: COMPARATOR
Intervention: Moderate weight gain (~6%) in MAO subjects
Number of subjects: 20
Study 25555214 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological pathways and genes associated with adipose tissue lipogenesis in MNO subjects
Number of subjects: 20
Study 25555214 — intervention group
Group type: COMPARATOR
Intervention: Biological pathways and genes associated with adipose tissue lipogenesis in MAO subjects
Number of subjects: 20
Study 25555267 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal cIMT (>0.90 mm)
Number of subjects: 673
Study 25555267 — intervention group
Group type: EXPERIMENTAL
Intervention: Age class 65-74 yrs.
Number of subjects: 673
Study 25555267 — intervention group
Group type: EXPERIMENTAL
Intervention: Age class ≥75 yrs.
Number of subjects: 673
Study 25555267 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial hypertension
Number of subjects: 673
Study 25555267 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-channel blockers use
Number of subjects: 673
Study 25555267 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent/permanent NVAF
Number of subjects: 673
Study 25555354 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg/day) for 7 days
Number of subjects: 30
Study 25555354 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA+DHA (2.6g/day) for 28 days
Number of subjects: 30
Study 25555354 — intervention group
Group type: EXPERIMENTAL
Intervention: Both aspirin and EPA+DHA for another 7 days
Number of subjects: 30
Study 25555420 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg orally once daily for 28-day cycles until disease progression or limiting toxicities
Number of subjects: 51
Study 25555420 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 51
Study 25555530 — intervention group
Group type: EXPERIMENTAL
Intervention: CFS patients
Number of subjects: 120
Study 25555530 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 120
Study 25556540 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased plasma concentration of apolipoprotein H (apoH)
Number of subjects: 189
Study 25556540 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein H (apoH)
Number of subjects: 189
Study 25556716 — intervention group
Group type: EXPERIMENTAL
Intervention: IGN523 (anti-CD98 antibody)
Number of subjects: 0
Study 25556837 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone maintenance dose
Number of subjects: 81
Study 25556837 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractioned methadone intake
Number of subjects: 81
Study 25556837 — intervention group
Group type: EXPERIMENTAL
Intervention: Bodyweight
Number of subjects: 81
Study 25556837 — intervention group
Group type: EXPERIMENTAL
Intervention: History of cocaine dependence
Number of subjects: 81
Study 25556837 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethnicity
Number of subjects: 81
Study 25556837 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver/intestinal CYP3A4 activity
Number of subjects: 81
Study 25556837 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant CYP3A4 inhibitors
Number of subjects: 81
Study 25556837 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic polymorphisms
Number of subjects: 81
Study 25557329 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal analgesic regimen (gabapentin, ketorolac, dexamethasone, acetaminophen, ibuprofen)
Number of subjects: 48
Study 25557584 — intervention group
Group type: EXPERIMENTAL
Intervention: Irish set dancing
Number of subjects: 10
Study 25557634 — intervention group
Group type: COMPARATOR
Intervention: Overweight/obese adults
Number of subjects: 527
Study 25557634 — intervention group
Group type: COMPARATOR
Intervention: Overweight/obese juveniles
Number of subjects: 527
Study 25557634 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight/obese juveniles and adults
Number of subjects: 527
Study 25557634 — intervention group
Group type: EXPERIMENTAL
Intervention: Juveniles with low vitD-status
Number of subjects: 527
Study 25557634 — intervention group
Group type: EXPERIMENTAL
Intervention: Juveniles and adults
Number of subjects: 527
Study 25558798 — intervention group
Group type: EXPERIMENTAL
Intervention: MusiQoL index score at 24 months
Number of subjects: 526
Study 25558798 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline EDSS score
Number of subjects: 526
Study 25558798 — intervention group
Group type: EXPERIMENTAL
Intervention: At least one relapse during follow-up
Number of subjects: 526
Study 25558798 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational status and marital status
Number of subjects: 526
Study 25558798 — intervention group
Group type: EXPERIMENTAL
Intervention: Sociodemographics (age, marital status, occupational status) and baseline QoL scores
Number of subjects: 526
Study 25558980 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative dose of morphine
Number of subjects: 259
Study 25558980 — intervention group
Group type: EXPERIMENTAL
Intervention: FAAH SNP, rs324420
Number of subjects: 259
Study 25559048 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervicovaginal lavage (CVL) with sterile saline and peripheral blood sample
Number of subjects: 34
Study 25559048 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF levels in symptomatic women
Number of subjects: 34
Study 25559048 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF levels in asymptomatic women
Number of subjects: 34